Laminar Pharma Receives Rare Pediatric Disease Designation from the U.S. FDA for LAM561
Laminar Pharmaceuticals S.A., empresa biotecnológica española en fase clínica centrada en el desarro...
11 September, 2023-
Next generation medicinesLearn moreWe design and develop drugs based on a novel therapeutic approach called melitherapy. -
A new pharmaceutical perspectiveLearn moreOur drugs are first-in-class molecules which target membrane lipids, instead of acting directly on proteins or DNA like other medicines.
-
Committed
to peopleLearn moreOur goal is to deliver reference treatments for illnesses with unmet medical needs, such as cancer and Alzheimer’s disease.
